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Diﬀerential toxicity of gold-doxorubicin in cancer
cells vs. cardiomyocytes as measured by real-time
growth assays and ﬂuorescence lifetime imaging
microscopy (FLIM)†
Eric Tawagi,a Charlotte Massmann,a,b Hicham Chiblia and Jay L. Nadeau*‡a
The kinetics of toxicity of doxorubicin (Dox) and gold nanoparticle-conjugated doxorubicin (Au-Dox)
were investigated in cultured B16 melanoma cells and cardiomyocytes using real-time cell-growth
imaging. Both bolus exposure and continuous exposure were used. Modeling of the growth curve
dynamics suggested patterns of uptake and/or expulsion of the drug that were diﬀerent for the diﬀerent
cell lines and exposures. Dox alone in B16 cells ﬁt to a model of slow drug buildup, whereas Au-Dox ﬁt to
a pattern of initial high drug eﬃcacy followed by a decrease. In cardiomyocytes, the best ﬁt was to a
model of increasing drug concentration which then began to decrease, consistent with breakdown of the
doxorubicin in solution. Cardiomyocytes were more sensitive than B16 cells to Dox alone (IC50 123 ± 2
nM vs. 270 ± 2 nM with continuous exposure), but were dramatically less sensitive to Au-Dox (IC50 1 ± 0.1
µM vs. 58 ± 5 nM with continuous exposure). Bolus exposure for 40 min led to signiﬁcant cell death in
B16 cells but not in cardiomyocytes. Fluorescence lifetime imaging (FLIM) showed diﬀerent patterns of
uptake of Au-Dox in the two cell types that explained the diﬀerential toxicity. While Au-Dox concentrated
in the nuclei of B16 cells, it remained endosomal in cardiomyocytes. These results suggest that stable
conjugates of nanoparticles to doxorubicin may be useful for treating resistant cancers while sparing
healthy tissue.
Introduction
Doxorubicin (Dox) is a cytostatic drug commonly used in the
chemical treatment of a wide range of cancers. Its major draw-
back is a delayed cardiomyopathy which limits the cumulative
dose given. Many pre-clinical and clinical studies have been
conducted to try to reduce cardiotoxicity of Dox.1 Current clini-
cal trials focus mostly on administration of beta-blockers, anti-
angiotensin agents, or iron chelators to high-risk patients
receiving Dox.2 Animal studies have investigated alternative
approaches such as exercise,3 dietary antioxidants,4,5 lipid-
lowering drugs,6 and topoisomerase II inhibitors7 to reduce
cell damage caused by Dox.
Encapsulation or conjugation of Dox into/onto nano-
particles can also be cardioprotective because of altered phar-
macokinetics and pharmacodynamics of the nanoparticle
formulation. The enhanced permeability and retention (EPR)
eﬀect causes nanoparticles to selectively accumulate in tumor
tissues, with less accumulation in healthy tissue, reducing
exposure of non-target organs to Dox.8,9 Clinical trials have
confirmed significant decreases in cardiotoxicity with both
PEGylated and non-PEGylated liposomal formulations of
Dox.10–12 An anthracycline, Dox has multiple modes of cyto-
toxic action, including intercalation into DNA.13 However, it
can also cause membrane damage; conjugation of Dox to large
particles that do not enter the nucleus does not eliminate Dox
toxicity14 but changes its mechanism of action from pure
apoptotic cell death to caspase-independent mechanisms.
Because of these altered kinetics and mechanisms, conjugated
Dox has been shown to be able to overcome cellular resistance
in cancer cells that have high native resistance or treatment-
induced resistance, such as melanoma cells.15,16 Our previous
research reported a stable conjugate of ultrasmall (2.7 nm) Au
nanoparticles to Dox, where tiopronin-capped Au particles are
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attached to Dox via an amide bond. Endpoint toxicity assays
showed that Au-Dox was up to 20-fold more cytotoxic to resist-
ant B16 murine melanoma cells than the equivalent concen-
tration of Dox alone. However, Au-Dox was less cytotoxic to
Dox-sensitive HeLa cells than was free Dox.17
There are several studies in the literature that examine the
in vitro pharmacokinetics of Dox and liposomal Dox,18–20 with
modeling and extraction of model parameters from end-point
cytotoxicity assays taken at diﬀerent time points. One study
compared free Dox and liposomal Dox in B16 cells, finding
that liposomal Dox was significantly more eﬀective at cell
killing and that it entered cells more quickly. Nevertheless, the
lag time between drug application and cell death was similar
for free and encapsulated drug.18 Another study modeled Dox
uptake after continuous or time-limited exposure to free drug
or drug encapsulated in protocells,19 finding a similar result
as with liposomes: the protocells entered the cells more
quickly and led to more eﬃcient cell death, particularly in
resistant cell lines. The importance of exposure time of the
drug and of drug uptake into subcellular compartments was
emphasized in a third study.20 Because of the multiple modes
of action of Dox, the rates of entry vary; membrane binding,
for example, occurs on a faster time scale than entry into
nuclei or mitochondria. Dox-resistant cells show diﬀerent rates
of uptake of Dox into diﬀerent cell compartments, as well as
diﬀerent threshold values.
In this study, we hypothesized that real-time imaging and
growth analysis of cells exposed to Dox and Au-Dox would
emphasize and help elucidate the diﬀerent mechanisms of
action of the two formulations. We tested this on a Dox-resist-
ant, fast-growing melanoma cell line (B16) as well as a rat myo-
cardial cell line with a slow division time and no resistance to
Dox. The real-time cell growth method is based upon a multi-
mode microplate platform coupled to an imaging cytometer.
The instrument uses phase-contrast microscopy along with
cell detection technology to analyze cell confluence without
the use of cell labeling. Growth curves were complemented by
fluorescence lifetime imaging (FLIM) analysis. FLIM is a con-
centration-independent imaging technique that is able to dis-
tinguish free from encapsulated Dox.21–24 We previously used
FLIM to observe uptake of Dox and Au-Dox into B16 cells,
finding that Au-Dox was able to enter cell nuclei after approxi-
mately 4 h of incubation. The intact Au-Dox conjugate could
be directly observed as a slow component to the lifetime.25
These techniques clearly illustrate patterns of uptake and/or
expulsion of free and conjugated doxorubicin that are diﬀerent
for the two cell lines. This has implications for designing Dox
conjugates that are more eﬀective against cancer cells and less
toxic to the heart.
Experimental
Cell culture
Cell types used were B16 melanoma cells (a gift of J. Teodoro
at the McGill Cancer Centre) and a myoblastic cell line (ATCC
CRL-1446) derived from embryonic BD1X rat heart tissue. The
cells were cultured in high-glucose DMEM (Invitrogen Canada,
Burlington, ON) supplemented with penicillin (100 U mL−1),
streptomycin (100 μg mL−1), and FBS (10%), and incubated in
a CO2 humidified atmosphere. Cells were passaged at 5 × 10
3
cells per well (for B16) or at 4 × 103 cells per well (for cardio-
myocytes) in 96 well culture plates 24 h before use. To obtain
even distribution of the cells, the culture plate was gently
rocked five times from left to right, and five times from far to
near for a total of five times, and left in the biosafety cabinet
for 40 min before placing into the incubator.
Synthesis of Au nanoparticles and Au-Dox
Ultrasmall particles capped with tiopronin were made by a
published method26 involving addition of hydrogen tetrachloro-
aureate(III) trihydrate and tiopronin (N-(2-mercaptopropionyl)
glycine) to an aqueous solution of sodium borohydrate. After
vigorous stirring for 30 min, the resulting black solution was
collected, concentrated, dissolved in H2O and dialyzed for 72 h
against dH2O (2 L), which was changed every 12 h. Particles
were characterized by transmission electron microscopy
(TEM), Fourier transform infrared spectroscopy (FTIR), and
absorbance/emission spectroscopy. For conjugation to Dox, a
solution of borate buﬀer (20 mM, pH 9) containing Au nano-
particles (1 µM), EDC (1 mM) and NHS (2 mM) was stirred for
1 h before adding the Dox to a final concentration of 25 µM.
The mixture was stirred at 25 °C for 12 h. The conjugates
were purified by ultrafiltration (Vivaspin 5000 KDa filters) and
resuspended in phosphate-buﬀered saline (PBS), pH 7.4. The
amount of Dox per Au nanoparticle was calculated based upon
the absorbance of Dox at 500 nm in the purified conjugates, as
reported previously.17
Toxicity studies
The IC50 of Dox and Au-Dox were determined using the SRB
assay and real-time growth curve imaging sequentially on the
same plates. When the cells were 60% confluent, the media
was removed and the cells were incubated with Dox alone or
Au-Dox at various concentrations in supplemented DMEM.
After 30 min, they were washed with PBS and incubated in
200 μL of supplemented DMEM. Next, the cells were imaged
on a SpectraMax® MiniMax 300 Imaging Cytometer (Molecular
Devices) with the transmitted light channel at diﬀerent time
points. Measurements took approximately 7 minutes and cells
were returned to the incubator between measurements.
Immediately after the last time point measurement, the cells
were fixed with trichloroacetic acid (65 μL of 40% v/v) at 4 °C
overnight, then washed five times with distilled water, air-
dried for at least 40 min, and stained with SRB reagent (sulfor-
hodamine B) (50 μL) for 30 min. Unbound SRB was removed
by washing four times with 1% acetic acid and the plate was
air-dried for at least 40 min; bound SRB was dissolved in Tris
(100 μL of 10 mM solution at pH 10.5). Absorbance was read at
510 nm using a SpectraMax® i3 microplate reader from Mole-
cular Devices.
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Cell imaging
Cells were imaged at 37 °C with the SpectraMax® MiniMax 300
Imaging Cytometer with predefined settings. Imaging was
done using the transmitted light channel and nine images per
well were taken. The confluence of the cells was then
measured with a custom user-defined field analysis setting on
the SoftMax Pro software (Molecular Devices). The region of
interest for each well delineated the middle ninth area. Four to
six cells with normal morphology, bright and diﬀerentiated,
were delineated as positive hits, while four to six dead cells,
darkened and rounded in addition to regions without cells
were delineated as negative hits. From our selections, the ana-
lysis was defined by the software and the eﬀectiveness of the
analysis was assessed qualitatively.
In order to determine the best approach to imaging-based
cytotoxicity, we tested two modes of cell analysis: object analysis
and field analysis. Object analysis measures the cell counts and
is reported as the number of cells per well (cell count). Field
analysis measures cell confluence and is reported as percentage
of the well area covered by cells (% area covered). The methods
were optimized on both B16 cells and cardiomyocytes by train-
ing the software with cell shapes of live (countable) and dead
(undesirable) cells in addition to color of dead cells using a trial
and error approach until the best cell demarcation was reached.
The selection and optimization process was reiterated at least
five times or until the analysis led to a majority of live cells
being chosen by the software at diﬀerent cell confluences.
Data analysis and curve fitting
Real-time growth curve data were analyzed using Mathematica
10 (Wolfram). Quality of fits was determined by sum of
squared errors (SSE); the number of free parameters was mini-
mized by checking the goodness of fit after eliminating each
parameter. The SRB data were evaluated using GraphPad
Prism and were fit to the Hill equation.
FLIM
Cells on glass-bottom dishes were incubated with Au-Dox at
1 µM of Dox (40 nM of Au) for 1 h or 4 h in Extreme DMEM
(Wisent, Quebec, Canada). After incubation, cells were washed
twice with PBS, fixed with 2% of paraformaldehyde at 4 °C for
10 min, and washed 3 times with ice-cold PBS before imaging
in PBS. Fluorescence lifetime images were acquired on a Zeiss
LSM710 SPAD microscope outfitted with a PicoQuant LSM
FLIM upgrade kit consisting of a FLIM excitation source,
internal laser bypass, and single-photon avalanche diode
(SPAD) detector. The excitation source was a 473 nm pulsed
laser operated at a 50 MHz pulse rate (time resolution, 400 ps).
Parameters were chosen so that unlabeled cell autofluore-
scence did not yield a measurable signal (zero counts). Signals
were collected with a 590 nm long-pass filter for 90s with the
pinhole open at 441.2 nm, and the gain set to 800. Data were
analysed using SymPhoTme 64 (PicoQuant). Lifetime decays
were fit to a dual exponential decay model of the form:
I=I0 ¼ A1et=τ1 þ A2et=τ2 ð1Þ
where A are the amplitudes and τ are the fluorescence life-
times. The instrument response function (IRF) was decon-
volved from the signal. Goodness-of-fit data and residuals were
used to gauge fit results; a χ2 between 0.9–1.1 and random dis-
tribution of residuals around the x-axis were necessary for a fit
to be considered accurate.
Results and discussion
Particle synthesis and characterization
Au nanoparticle size can be controlled by the concentration of
reductants in the reaction. We chose to produce particles of
∼3 nm as our previous results had found that particles of this
size were able to enter cell nuclei, and that Au-Dox conjugates
using these particles were eﬀective against B16 melanoma
in vitro17 and in vivo.27 As produced, the Au-tiopronin nano-
particles were uniform in size, with a diameter of 2.7 ± 0.8 nm
as measured by transmission electron microscopy (Fig. 1).
Approximately 25 Dox molecules were attached per particle by
an amide bond between the carboxylate of the tiopronin and
the primary amine of Dox (ESI Fig. S1† for a schematic). This
is a stable bond that does not release measurable free Dox
after 24 h4 at pH 5 or ph 7.25
Image acquisition for real-time cell proliferation curves
Field analysis proved to be more reliable than object analysis
for the cell proliferation measurements, as object analysis
failed to detect all the desired cells (See ESI Fig. S2†). This was
therefore the method used for all of the cytotoxicity experi-
ments. The wells on the perimeter of the plate (outermost
wells) were plated with cells for comparison but were not ana-
lyzed because of edge eﬀects. More rapid evaporation in those
wells caused cells to aggregate towards the outer edges, result-
ing in non-uniform cell coating. Similarly, when choosing the
area to analyze, it was preferable to choose the centers of the
wells because of non-uniform growth and diﬃculties with
Fig. 1 Characterization of Au nanoparticles and conjugates. (A) TEM
image of Au nanoparticles. (B) High-resolution TEM showing crystal
structure of a single particle. (C) Histogram of particle sizes for >2000
particles.
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imaging at the edges of the wells. Both imaging methods
yielded B16 doubling times of 12 ± 1 h, consistent with litera-
ture results (see ESI Fig. S3†).
As expected, the cells’ features were aﬀected by the drugs.
In Dox-treated cells, morphological changes commonly
observed in apoptotic cells were apparent (shrinkage, round-
ing, detachment)28 in addition to significant darkening of the
cells29 (Fig. 2). Au-Dox appeared similar, but with more cell
shrinkage associated with caspase-independent cell death, and
with comparable amounts of cell death occurring at lower con-
centrations than with Dox alone (Fig. 3).
Real-time growth curves illustrate diﬀerent kinetics of Dox and
Au-Dox
B16 cells with short drug exposure (washed). Real-time
curves of cell confluence as measured by the field analysis
method are shown in Fig. 4 for B16 cells exposed to doxo-
rubicin or Au-Dox for 40 minutes, then washed (time 0 is
measured from when the drug was added). In the absence of
drug. growth is described by the logistic equation
dN
dt
¼ cN 1 N
Nmax
 
; ð2Þ
where N is the number of cells, k is a growth rate, and Nmax is
the maximum number of cells in the well (or, for field analysis,
the maximum confluence as measured by the value at plateau
in the absence of drug). The solution to this is a Boltzmann
sigmoid30
NðtÞ ¼ Nmax
1þ Nmax  N0
N0
 
ect
;
Nmax
1þ eðN50kÞt ð3Þ
Fig. 2 Phase-contrast images of B16 cells after (A–C) 0.5, (D–F) 24, and
(G–I) 48 h of exposure to doxorubicin at 0 µM, 5 µM, and 100 µM.
Fig. 3 Phase-contrast images of B16 cells after (A–C) 0.5, (D–F) 24, and
(G–I) 48 h of exposure to Au-Dox at (1) 0 µM, (2) 0.6 µM and (3) 50 µM.
Note the shrunken appearance of the cells in Panel F as compared with
the same panel in Fig. 2. Slight focusing diﬀerences along with diﬀer-
ences in melanin expression account for the diﬀerence in appearance of
the untreated cells.
Fig. 4 Growth curves and dose–response for B16 cells exposed to
drug for 40 minutes, then washed. (A) Real-time plot of B16 cell conﬂu-
ence after incubation with Doxorubicin at 0, 0.01, 0.1, 1, 5, 10, 17.5, 25,
50, and 100 µM and (B) Real-time plot of B16 cell conﬂuence after incu-
bation with Au-Dox at 0, 0.01, 0.05, 0.1, 0.6, 1.0, 2.0, 10, and 50 µM. The
data points are measurements, and the curves are ﬁts to eqn (6) or (7)
with parameters given in Table 1. Each data point is the mean of six
replicates with error bars indicating standard error of the mean (SEM).
(C) Dose–response at 24 h. The curve for Dox had not plateaued and
thus did not yield a reliable IC50 value. (D) Curves at 48 h showing
maximal eﬀect for both drugs. (See Table 3 for ﬁt values).
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where N0 is the number of cells at time t = 0, and N50 is
defined as the half-maximum point of the curve. With the
addition of drug, a death term b is introduced into eqn (1),
giving
dN
dt
¼ bN þ cN 1 N
Nmax
 
: ð4Þ
This equation may also be solved analytically to yield a
similar sigmoid form that is a function of c − b:
NðtÞ ¼ ðc bÞNmax
c eðcbÞte iπþlog N0logððcbÞNmaxcN0Þ½  ð5Þ
However, this is only applicable when the drug concen-
tration is constant at its site of action. Given the slow uptake
rate of Dox, it was necessary to take into account a time delay
for accumulation. This may be modeled as a concentration
that plateaus after a characteristic time a31,32:
dN
dt
¼ bð1 et=aÞN þ cN 1 N
Nmax
 
ð6Þ
The plateau phase decreased in duration with increasing
drug concentration, lasting ∼20 h at 10 µM and only ∼10 h at
100 µM (Fig. 4A, Table 1). The values of a correspond to the
physically measurable duration of the plateau before cell
death. The absolute values of b and c do not have physical
meaning, but their ratio gives a measure of cell killing vs. cell
growth; c/b was almost a monotonically decreasing function of
concentration for free Dox, with the exception being a spike at
the lowest concentrations (Table 1).
The diﬀerent kinetics of Au-Dox were apparent from the
growth curves. Au-Dox was cytotoxic at lower eﬀective Dox con-
centrations, and without a delay. The curves resembled sig-
moids, but with an initial drop in cell confluence followed by a
sigmoidal rise. The best fit was to an equation where concen-
tration of the drug began at its highest level and then
decreased:
dN
dt
¼ bðeatÞN þ cN 1 N
Nmax
 
ð7Þ
There was some recovery of cells in the Au-Dox case after
∼40 h. This was not seen with Dox alone (Fig. 4B). The values
of c/b were markedly smaller than for free Dox even for low
concentrations of Au-Dox (Table 1), suggesting that cell killing
dominated cell growth even for low concentrations. The spike
at low concentrations was also seen here; sub-toxic concen-
trations of Dox have been shown to stimulate cell growth,
especially if the medium is sub-optimal,33 consistent with our
measurements.
A half inhibition constant (IC50) of a drug could be esti-
mated at any time point from the real-time growth curves by
taking a slice through the data curve at the selected time point
to yield a concentration-dependent curve. Fig. 4C shows the
results at 24 h, which illustrated that Dox alone had not yet
had its full eﬀect. Even at the highest concentrations, many
cells remained. Because the curve did not reach a lower limit,
an IC50 value could not reliably be determined. On the other
hand, Au-Dox had already achieved maximal eﬀects at concen-
trations ≥1 µM. Fig. 4D shows the results at 48 h, where IC50
values could be determined for both Dox (16 µM) and Au-Dox
(610 nM). This indicates more than a 20-fold increase in the
cytotoxicity of Au-conjugated Dox relative to Dox alone in the
case of short exposure followed by washing, in good agreement
with previous work.17 The values obtained from the real-time
growth curves at 48 h were compared with results from the
SRB endpoint assay and found to agree within 10% (see ESI,
Fig. S4†).
B16 cells with continuous exposure (unwashed). When Dox
was not removed from the cells during incubation, the initial
plateau before cytotoxicity was not seen. Both Dox and Au-Dox
curves fit best to eqn (7), although in the case of Au-Dox, con-
centrations above 100 nM led to simple exponential decay of
cells (Fig. 4A and B). The IC50 of Dox alone was reduced 60-
fold, to 270 nM (Fig. 5C). For Au-Dox, the IC50 was reduced
8-fold, to 58 nM, with full eﬀects apparent as early as 8 h post
exposure (Fig. 5D).
Cardiomyocytes. Because of the slow doubling time of the
cardiomyocytes, measurements were carried out for 72 h after
drug addition. Washing of cells after 40 min did not lead to
significant cell death even at 5 µM (see ESI Fig. S5†). This was
probably due to the shortness of the exposure time relative to
the cell cycle time.34 When drug was applied without washing,
neither eqn (6) nor (7) yielded a good fit to the data. An
Table 1 Fits to eqn (6) (for Dox alone washed) or eqn (7) (for Dox alone
unwashed and Au-Dox both washed and unwashed) according to drug
and concentration
a b c c/b
B16 Control 0 0 0.15 —
B16Dox alone 0.01 µM 2.90 0.011 0.075 6.82
B16Dox alone 0.1 µM 0.109 0.0027 0.075 27.8
B16Dox alone 1 µM 2.99 0.024 0.118 4.92
B16Dox alone 5 µM 1.93 0.017 0.064 3.76
B16Dox alone 10 µM 1.00 0.019 0.05 2.63
B16Dox alone 17.5 µM 5.05 0.132 0.216 1.64
B16Dox alone 25 µM 10.2 0.198 0.221 1.12
B16Dox alone 50 µM 20.4 0.272 0.195 0.717
B16Dox alone 100 µM 10.3 0.111 0.067 0.604
Dox 0.01 µM unwashed 0.995 0.078 0.094 1.21
Dox 0.1 µM unwashed 0.047 0.079 0.116 1.47
Dox 0.3 µM unwashed 0.461 0.189 0.044 0.233
Dox 1 µM unwashed 0.732 0.129 0.020 0.155
Dox 6 µM unwashed 0 0.003 0 0
B16AuDox 0.01 µM 0.050 0.263 0.259 0.98
B16AuDox 0.05 µM 0.050 0.170 0.210 1.24
B16AuDox 0.1 µM 0.050 0.011 0.043 3.91
B16AuDox 0.6 µM 0.011 0.342 0.482 1.41
B16AuDox 1 µM 0.008 0.489 0.500 1.02
B16AuDox 2 µM 0.006 0.453 0.500 1.10
B16AuDox 5 µM 0.002 0.487 0.500 1.03
B16AuDox 10 µM 0 0.171 0.154 0.901
B16AuDox 50 µM 0 0.044 0 0
AuDox 0.01 µM unwashed 0 0.013 0.157 12.1
AuDox 0.05 µM unwashed 0 0.007 0.116 16.6
AuDox 0.1 µM unwashed 0 0.037 0 0
AuDox 0.6 µM unwashed 0 0.071 0 0
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equation with 4 parameters, modeling the drug concentration
as a parabola, was able to fit both the early plateau phase and
the late recovery seen in these cells:
dN
dt
¼ bðatþ dt2ÞN þ cN 1 N
Nmax
 
ð8Þ
Fig. 6A, B and Table 2 give the results of fits to eqn (8).
Fig. 6C and D shows dose–response at 48 h, showing that
cardiomyocytes were somewhat more sensitive than B16 cells
to Dox alone (IC50 of ∼120 vs. 270 nM), but much less sensitive
to Au-Dox (IC50 of 1 µM vs. 58 nM).
The parameters a and d should not be considered to have
much physical meaning on their own, but plots of the eﬀective
drug concentration parabolas defined by the parameters illus-
trate the diﬀerent kinetics of Dox and Au-Dox. The eﬀective
concentration of Dox alone climbed rapidly and then rapidly
decayed. However, the eﬀective concentration of Au-Dox fell
much more slowly; these curves could be approximated by
eqn (5), whereas the Dox-alone values were very poorly fit to
eqn (5) (Fig. 7). These results are consistent with previous
studies investigating the stability of Dox in aqueous solution.
Dox is most stable at acidic pH (pH 4) and 4 °C, but degrades
at physiological pH and temperature, with a half-life of 50 h at
37 °C in phosphate buﬀer.35 This matches very well the time
course of the cardiomyocyte experiments; the experiments
with B16 cells did not go on long enough for degradation to
play a significant role. Conjugation to the gold appears to have
delayed the ordinary breakdown process of the drug.
FLIM. In our previous work,36 we characterized the lifetimes
of Dox and Au-Dox in solution and in B16 cells using FLIM.
Free Dox shows a longer lifetime in cell cytoplasm (∼2.5 ns)
than in nucleus (∼1.2 ns); an additional small reduction in
lifetime has been reported when free Dox intercalates DNA,
Fig. 5 Growth curves and dose–response for B16 cells exposed to drug
continuously without washing. (A) Real-time plot of B16 cell conﬂuence
after incubation with Doxorubicin at 0, 0.01, 0.1, 0.3, 0.6, 1, and 20 µM.
(B) Real-time plot of B16 cell conﬂuence after incubation with Au-Dox
at 0, 0.01, 0.025, 0.05, 0.1, 0.3, 0.6, 1, 6, and 20 µM. The data points are
measurements, and the curves are ﬁts to eqn (7) with parameters given
in Table 1. Each data point is the mean of six replicates with error bars
indicating standard error of the mean (SEM). (C) Dose–response for Dox
alone at 8, 24, and 48 h. (D) Dose–response for Au-Dox at 8, 24, and
48 h (see Table 3 for ﬁt values).
Fig. 6 Growth curves and dose–response for cardiomyocytes exposed
to drug continuously without washing. (A) Real-time plot of cell conﬂu-
ence after incubation with Doxorubicin at 0, 0.1, 1, 2, 5 µM. (B) Real-time
plot of cell conﬂuence after incubation with Au-Dox at 0, 0.1, 1, 2, and 5
µM. The data points are measurements, and the curves are ﬁts to eqn (8)
with parameters given in Table 2. Each data point is the mean of six
replicates with error bars indicating standard error of the mean (SEM).
(C) Dose–response for Dox alone at 48 h comparing B16 cells and cardi-
omyocytes (CM). (D) Dose–response for Au-Dox at 48 h comparing B16
cells and cardiomyocytes (CM).
Table 2 Fits to eqn (8) for Dox alone Au-Dox unwashed applied to car-
diomyocytes (CM)
a b c c/b d
CM control 0 0 0.057 — 0
CM Dox alone 100 nM 0.487 1.58 × 10−3 0.051 0.057 −5.31 × 10−3
CM Dox alone 1 µM 0.174 0.012 0.028 0.051 −2.40 × 10−3
CM Dox alone 2 µM 0.230 9.53 × 10−3 0.035 0.028 −2.92 × 10−3
CM Dox alone 5 µM 0.209 9.80 × 10−3 0.027 0.035 −2.80 × 10−3
CM AuDox 100 nM 0.151 1.31 × 10−3 0.055 0.027 −1.31 × 10−3
CM AuDox 1 µM 0.223 3.61 × 10−3 0.040 0.055 −2.30 × 10−3
CM AuDox 2 µM 0.088 0.018 0.010 0.040 −1.37 × 10−3
CM AuDox 5 µM 0.166 3.13 × 10−3 −0.020 <0 −3.91 × 10−3
Table 3 IC50 values for the diﬀerent experimental conditions deter-
mined at the 48 h time point. CM, cardiomyocytes. The values for
washed CM were not determined. The errors represent standard errors
from the curve ﬁt
Condition IC50 at 48 h Dox IC50 at 48 h Au-Dox
B16 washed 16 ± 1 µM 610 ± 2 nM
B16 unwashed 270 ± 2 nM 58 ± 5 nM
CM unwashed 123 ± 2 nM 1.0 ± 0.1 µM
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but this is diﬃcult to resolve in cells. In solution, Au-Dox does
not show a significant diﬀerence in lifetime compared to Dox
alone, but in cells it is visible as a long-lifetime component
(∼4 ns). This component may be replicated in situ by adding
lipids or membranes to Au-Dox, indicating that the long life-
time component results from membrane association. Au-Dox
lifetimes do not change with DNA addition, so it is not poss-
ible to determine whether Au-Dox intercalates DNA using
FLIM.
In the current study, we observed intact Au-Dox using FLIM
by monitoring the long-lifetime component. In B16 cells, this
long component appeared after 4 hours of incubation,
showing that Au-Dox entered the nucleus somewhat more
slowly than the rest of the cell (Fig. 8A and B). Intensity images
showed the highest fluorescence intensity in the nucleus and
nuclear membrane of B16 cells (Fig. 8C). However, when per-
forming these experiments with cardiomyocytes, we observed a
diﬀerent pattern. After 4 h, the lifetime in the nucleus was
equivalent to that of Dox alone, with no slow component
(Fig. 8D and E). Intensities were greatest in the perinuclear
region, corresponding to endosomes/lysosomes (Fig. 8F). Two-
exponential fits to lifetimes in the diﬀerent compartments
showed comparable values between B16 and cardiomyocytes
in the cytoplasm at 1 and 4 h and in the nucleus at 1 h, but a
striking diﬀerence in the slow component in the nucleus at
4 h (Fig. 9, Table S1†).
Diﬀerences between B16 cells and cardiomyocytes. Taken
together, the growth curves and imaging results help explain
the observed diﬀerences in IC50 observed in the two cell lines.
Dox is a cell-cycle-dependent drug that is most eﬀective
against cells in the S and G2/M phase, and causes cell-cycle
arrest in G2/M followed by apoptosis.37 The growth curves for
cardiomyocytes (Fig. 5) show similar patterns for Dox and
Au-Dox, with growth inhibition at 0.1 µM free Dox or 1 µM
Fig. 7 Parabolic ﬁts to eﬀective drug concentrations (eqn (8)) for Dox
and Au-Dox at two concentrations. Note the steeper slope of decline
for Dox alone.
Fig. 8 FLIM images of B16 cells and cardiomyocytes exposed to Dox and Au-Dox. Scale bars are 10 µm; color-coded lifetime scale represents
average lifetime and applies to all panels. (A) B16 with free Dox after 4 h. (B) B16 with Au-Dox after 4 h. (C) Intensity image of B16 with Au-Dox after 4 h.
(D) Cardiomyocytes with free Dox after 4 h. (E) Cardiomyocytes with Au-Dox after 4 h. (F) Intensity image of cardiomyocytes with Au-Dox after 4 h.
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Au-Dox. Combined with the imaging results, these curves
suggest that Au-Dox is working in a similar fashion in these
cells as free Dox. The conjugate is taken up into endosomes,
and some free Dox is liberated by endosomal enzymes, where
it is then able to enter the nucleus; eﬀective concentrations
with Au-Dox are lower than for free Dox since activity depends
upon release. Future experiments will examine cell-cycle-syn-
chronized cultures to determine the exact eﬀects of cell cycle
on toxicity, and will examine the eﬀects of washing cells after
incubation periods longer than 40 minutes.
In contrast to the cardiomyocytes, the mechanisms of
action of Au-Dox vs. free Dox are diﬀerent in B16 cells (Fig. 3
and 4). Free Dox delivered as a 40-min bolus shows a signifi-
cant lag time before becoming eﬀective, whereas Au-Dox is
eﬀective immediately. When the drug is not removed, Au-Dox
leads to complete cell death at very low concentrations (100
nM and higher). A large number of studies have shown
increased eﬀectiveness of nanoparticle formulations of Dox in
resistant cancer cells.38 However, these formulations are all
diﬀerent from the one presented here, as nearly all of them
focus upon drug release as a goal, with the nanoparticle being
a delivery vehicle; none of them show intact entry of the conju-
gate into the nucleus. Examples of such constructs are Au-Dox
made with a cleavable hydrazone bond,39 and carbon nano-
tubes (CNTs) with Dox adsorbed by pi-stacking.40 When the
particles enter the cells, Dox is realeased and the free Dox
enters the nucleus. These constructs are more eﬀective against
cancer cells than free Dox because of a reduced ability of the
eﬄux pumps to expel the nanoparticle-bound Dox. Some other
nanoparticle types release a modified form of Dox near the
membrane that is not recognized by P-glycoprotein, the main
moderator of resistance.38 Some stable constructs have also
been reported, such as Dox-transferrin, which do not release
any Dox into the nucleus but which appear to kill cells
through other mechanisms, such as membrane damage. Dox-
transferrin is more eﬀective against cancer cells than normal
cells because of the overexpression of transferrin receptors by
cancer cells, which results in greater nanoparticle uptake.14,16
Our conjugate is stable to hydrolysis and is found in the
nuclei of B16 cells much more rapidly than can be explained
by entry during mitosis. Thus, it appears that the construct
either diﬀuses through the nucleopores or damages the
nuclear membrane to an extent that permits entry. The FLIM
and fluorescence intensity images do show enhancement of
both the nuclear and nucleolar membranes, suggesting that
Au-Dox associates primarily with membranes, though due to
the small size it is certainly possible for it to pass through
nucleopores, where the limit is ∼6 nm.41 The exact mecha-
nisms of why this occurs to a great extent in B16 cells,
and little or not at all in cardiomyocytes, remain to be
explored. The kinetics of binding and entry of these ultra-
small particles also remains to be quantified, as the small size
makes tracking individual particles diﬃcult even by electron
microscopy.
Numerous studies have shown that Dox resistance in cancer
cells is primarily due to resistance to apoptosis.42 Our first
Fig. 9 Lifetime decay curves and ﬁts. The solid black lines show ﬁts
with residuals given underneath the plots. (A) Cytoplasm after 4 h of
incubation showing Au-Dox in B16 cells (red curve) and in CM (light
blue). The free Dox curves for the 2 cell types overlapped, so only one
curve is shown (“free Dox,” dark blue). (B) Nucleus after 4 h of incubation
showing Au-Dox in B16 cells (red) and CM (light blue). The free Dox
curves for the 2 cell types overlapped so only one curve is shown (“free
Dox,” dark blue). (C) Fit values for dual-exponential ﬁts to the fast and
slow lifetime components in cytoplasm (cyto) and nucleus (nuc) after
1 and 4 h of incubation. The fast components (including the single com-
ponent for free Dox) were equivalent in the two cell types. The slow
component showed a dramatic diﬀerence between CM and B16 cells at
4 h, which was not seen at 1 h. The values are means of 7–10 regions or
cells with error bars indicating standard deviation; when error bars do
not appear, they are smaller than the symbols. The lines are guides for
the eye. The values are given in the ESI, Table S1.†
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study using ultrasmall Au-Dox showed that transfecting Dox-
sensitive cells with the anti-apoptotic protein Bcl-2 protected
them against Dox but not against Au-Dox.17 Au-Dox leads
primarily to non-apoptotic cell death,27 and is thus able to
overcome this resistance. In Dox-sensitive cells, such as cardio-
myocytes, this non-apoptotic mechanism is somewhat less
eﬀective than the apoptosis caused by free Dox, probably
because the bound Au-Dox does not enter the nucleus. Thus
Au-Dox is only expected to be more eﬀective than free Dox in
cells that are resistant to apoptosis.
Conclusions
Dox alone in B16 cells fits to a model of slow drug buildup,
whereas Au-Dox fits to a pattern of initial high drug eﬃcacy
followed by a decrease. In cardiomyocytes, the best fit is to a
model of increasing drug concentration which then begins to
decrease. Cardiomyocytes are less sensitive to Au-Dox than to
Dox alone, the opposite of what is seen in B16 cells. FLIM
imaging reveals a striking diﬀerence between the two cell
types: while Au-Dox enters the nuclei of B16 cells, only free
Dox enters cardiomyocyte nuclei. The pattern of uptake in the
cardiomyocytes is almost entirely endosomal. These results
suggest that conjugated Au-Dox is a useful agent for overcom-
ing Dox resistance of apoptosis-resistant cancer cells, and that
it might reduce toxicity to non-target organs, particularly the
heart.
In addition, the real-time imaging technique is of general
utility and provides a rapid, less labor-intensive approach
to development of quantitative drug uptake and cell-killing
models.
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